Acute Kidney Injury (AKI) - Epidemiology Forecast - 2032

This Acute Kidney Injury - Epidemiology Forecast- 2032” report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Acute Kidney Injury Disease Understanding and Treatment Algorithm

Acute Kidney Injury Overview

AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. Signs and symptoms of AKI includes, nausea, vomiting, weakness, dizziness and, pain in lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.

Acute Kidney Injury Diagnosis

The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or fall in urine output. The laboratory assessment includes the measurement of Serum Creatinine Level, Urinalysis, renal biopsy and others.

Acute Kidney Injury Treatment

The treatment for AKI depends on the cause of the condition. Most people need to stay in the hospital during treatment and until the recovery of the kidneys. Some possible treatments include temporary hemodialysis, medicines to control the amounts of vitamins and minerals in blood, treatments to keep the right amount of fluid in the blood. There is no approved treatment for AKI, the current treatment practices use conventional therapies (vasopressor, diuretics, statins and others) and renal replacement therapies.

Acute Kidney Injury Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of AKI in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI and, Age-specific Incident Population of AKI in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the AKI epidemiology in the 7MM

Country Wise- Acute Kidney Injury Epidemiology

• The epidemiology segment also provides the AKI epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised of 6,470,038 cases in 2021 and are projected to increase during the forecast period.
• The total Mortality-adjusted Incident Cases of AKI in the United States is 2,210,647 in 2021.
• The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.
• Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
• In Japan, the total mortality-adjusted Incident Cases of AKI was 1,272,824 in 2021 and is anticipated to rise during the forecast period.
• The stage-specific cases of AKI includes stage I, Stage II and, stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.

Scope of the Report

• The report covers the descriptive overview of AKI, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the AKI epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for AKI are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of AKI market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM AKI market.

Report Highlights

• In the coming years, AKI market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence AKI R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• As per the analysis the subtypes- specific of AKI include Stage I, Stage II and Stage III.

AKI Report Insights

• Patient Population
• Therapeutic Approaches
• 7MM Coverage
• AKI Epidemiology Segmentation

Key Questions Answered

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of AKI?
• What is the historical AKI patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of AKI at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to AKI?
• Out of the above-mentioned countries, which country would have the highest incident population of AKI during the study period (2019-2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the AKI.
• To understand the future market competition in the AKI market and Insightful review of the SWOT analysis of AKI.
• Organize sales and marketing efforts by identifying the best opportunities for AKI in the US, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• The AKI Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.